ORAMED PHARMACEUTICALS INC

Oramed insider Hexter Joshua’s July 1 sell‑buy reveals strategic rebalancing: selling 137k shares then buying 50k at lower price, boosting long‑term confidence in the oral‑delivery platform.

Oramed’s CEO and senior execs buy RSUs—showing insider confidence in the company’s oral insulin launch, Phase II success, and potential market‑access boost.

Oramed’s insider buying signals confidence in its oral‑insulin platform, offering a safe, effective non‑injectable therapy with strong Phase 2/3 data and upcoming FDA milestones.